Evaluation of the effectiveness of biotin and dexpanthenol ampoules produced by Pars Behruzan Jam company in reducing hair loss

Evaluation of the effectiveness of biotin and dexpanthenol ampoules produced by Pars Behruzan Jam company in comparison with reference drugs (produced by Bayer German company) in reducing diffuse and scattered hair loss

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190210042676N10

Enrollment

Registered

2020-07-19

Start date

2020-07-22

Completion date

Unknown

Last updated

2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hair loss. Nonscarring hair loss, unspecified

Interventions

Intervention 1: Intervention group: Injection of 6 ampoules of Dexpanthenol 250 mg / 2 ml, produced by Pars Behruzan Jam Company, as a muscle injection, within 6 weeks+Injection of 6 ampoules of Bioti

Eligibility

Sex/Gender

All

Age

18 Years to 55 Years

Inclusion criteria

Inclusion criteria: Male or female aged 18-55 years diffuse and scattered hair loss General health Voluntary participation and signing written informed consent

Exclusion criteria

Exclusion criteria: Pregnancy or breastfeeding Chronic active scalp disease other than hair loss Using any prescribed drug or OTC for hair loss within the past 3 months People with allergies to drug ingredients Any severe weight loss or strict diet therapy during the study

Design outcomes

Primary

Measure	Time frame
Hair lost Changes, based on Global photographic review. Timepoint: Before intervention, 1 and 8 weeks after last injection. Method of measurement: One independent dermatologist will perform clinical assessments in a blinded fashion by scoring every photograph according to the Global photographic review scale .	—

Secondary

Measure	Time frame
Hair count changes. Timepoint: Before intervention, 1 and 8 weeks after last injection. Method of measurement: Dermatoscopy By Fotofinder.;Changes in percentage of anagen to telogen. Timepoint: Before intervention, 1 and 8 weeks after last injection. Method of measurement: Dermatoscopy By Fotofinder.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAniseh Samadi

Tehran University of Medical Sciences

aniseh_samadi@yahoo.com+98 21 8896 0880

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026